Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Down 45.2% in December

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the recipient of a significant decline in short interest during the month of December. As of December 31st, there was short interest totalling 37,100 shares, a decline of 45.2% from the December 15th total of 67,700 shares. Currently, 2.8% of the shares of the stock are short sold. Based on an average trading volume of 307,000 shares, the short-interest ratio is currently 0.1 days.

Hedge Funds Weigh In On Sonoma Pharmaceuticals

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC bought a new position in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned about 1.08% of Sonoma Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 1.95% of the company’s stock.

Sonoma Pharmaceuticals Trading Up 1.5 %

NASDAQ SNOA traded up $0.04 during trading on Thursday, hitting $2.66. 53,750 shares of the company’s stock were exchanged, compared to its average volume of 43,035. The stock’s 50 day moving average price is $2.73 and its two-hundred day moving average price is $2.12. Sonoma Pharmaceuticals has a fifty-two week low of $2.44 and a fifty-two week high of $9.37. The company has a market cap of $3.56 million, a PE ratio of -0.53 and a beta of 1.41.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.